Haemophilus Influenzae Type Meningitis

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2026-02-12
EMA Authorised: Infanrix Hexa (Diphtheria toxoid;tetanus toxoid;Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin);hepatitis B surface antigen;poliovirus (inactivated) (type-1 (Mahoney strain), type-2 (MEF-1 strain), type-3 (Saukett strain));Haemophilus influenzae type b polysaccharide) — GlaxoSmithKline Biologicals S.A.
The European Medicines Agency authorised Infanrix Hexa, a hexavalent vaccine that combines diphtheria, tetanus, pertussis, hepatitis B, poli…
EMA approval · 2025-09-29
EMA Authorised: Hexyon (filamentous haemagglutinin;Haemophilus influenzae type B polysaccharide (polyribosylribitol phosphate);hepatitis B surface antigen;pertussis toxoid;poliovirus (inactivated) type 1 (Mahoney strain) produced on Vero cells;poliovirus (inactivated) type 2 (MEF-1 strain) produced on Vero cells;poliovirus (inactivated) type 3 (Saukett strain) produced on Vero cells;tetanus protein;tetanus toxoid adsorbed on aluminium hydroxide, hydrated;Diphtheria toxoid) — Sanofi Winthrop Industrie
EMA authorised Hexyon, a hexavalent vaccine combining protection against hepatitis B, diphtheria, tetanus, pertussis, Haemophilus influenzae…
FDA approval · 2021-09-13
FDA Approved: RIFAMPIN — Supplemental Application (EPIC PHARMA, LLC)
The FDA approved a supplemental application for Rifampin from Epic Pharma, LLC. The action pertains to changes under the Rifampin ANDA 06415…